Semaglutide is administered via subcutaneous injection and has shown significant benefits in weight loss in clinical trials, leading to its approval for obesity treatment as well
Whether this applies to humans is not established, but both carry a FDA boxed warning and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2)
* All results refer to participation in MDWatchs Program, which combines personalized coaching, nutrition and lifestyle support, exercise, and, when clinically appropriate, compounded GLP-1 medication dispensed by licensed pharmacies pursuant to a prescription
Yes, Ozempic is an adjunct therapy
The key difference lies not just in the treatment itself but in how its delivered and supported